NYSE · Healthcare
Ginkgo Bioworks Holdings, Inc. (DNA)
As-reported financials and recent SEC filings for Ginkgo Bioworks Holdings, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$170.2M
Net income
$-312.8M
Net margin
—
Diluted EPS
$-5.64
ROE
-61.5%
P/E (TTM)
—
Market cap
$669.6M
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $170.2M | $227.0M | $251.5M | $477.7M | $313.8M |
| Gross profit | — | — | — | — | — |
| Operating income | $-315.3M | $-559.8M | $-864.4M | $-2.21B | $-1.83B |
| Net income | $-312.8M | $-547.0M | $-892.9M | $-2.10B | $-1.83B |
| Diluted EPS | $-5.64 | $-10.54 | $-18.37 | $-50.20 | $-44.48 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →8-K2026-06-12
View on EDGAR →1442026-06-10
View on EDGAR →42026-05-26
View on EDGAR →1442026-05-22
View on EDGAR →Go deeper on DNA
Search Ginkgo Bioworks Holdings, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.